Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: Report of a randomized comparative trial

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 5, 2004, Pages 1369-1377

  Komaki, Ritsuko ^a   Lee, Jin Soo ^c   Milas, Luka ^b   Lee, Hoon K ^a   Fossella, Frank V ^a   Herbst, Roy S ^a   Allen, Pamela K ^a   Liao, Zhongxing ^a   Stevens, Craig W ^a   Lu, Charles ^a   Zinner, Ralph G ^a   Papadimitrakopoulou, Vassiliki A ^a   Kies, Merrill S ^a   Blumenschein Jr , George R ^a   Pisters, Katherine M ^a   Glisson, Bonnie S ^a   Kurie, Johnathan ^a   Kaplan, Bunyamin ^a   Garza, Veronica P ^a   Mooring, Deidre ^a   Tucker, Susan L ^a   Cox, James D ^a   more..

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c National Cancer Center   (South Korea)

Author keywords

Cytoprotection; Non small cell lung cancer; Randomized controlled trial

Indexed keywords

CELLS; CHEMOTHERAPY; PATIENT MONITORING; PULMONARY DISEASES; RADIOTHERAPY; TOXICITY;

CONCURRENT CHEMOTHERAPY; LUNG CANCER;

TUMORS;

AMIFOSTINE; ANALGESIC AGENT; CISPLATIN; DIURETIC AGENT; ETOPOSIDE; STEROID;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DYSGEUSIA; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS DISEASE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; INCIDENCE; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SNEEZING; SURVIVAL TIME; SWALLOWING; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 12144286602     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.005     Document Type: Article

References (25)

1. Lee J.S., Komaki R., Fossella F.V., et al. A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer A 5-year follow-up report. Int J Radiat Oncol Biol Phys. 42:1998;479-486.
2. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol. 14:1996;1055-1064.
3. Komaki R., Scott C., Ettinger D., et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer Radiation Therapy Oncology Group (RTOG) 9204. Int J Radiat Oncol Biol Phys. 38:1997;149-155.
4. Komaki R., Scott C., Lee J.S., et al. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC) Comparison of RTOG 83-11 and RTOG 91-06. Am J Clin Oncol. 20:1997;435-440.
5. Langer C.J., Hsu C., Curran W., et al. Do elderly patients (pt) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? A secondary analysis of RTOG 94-10. Int J Radiat Oncol Biol Phys. 51:2001;20-21.
6. Liao Z., Komaki R., Stevens C., et al. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 53:2002;558-565.
7. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 18:2000;3339-3345.
8. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 14:1996;2101-2112.
9. Andreassen C.N., Lindegaard J.C. Chemical radioprotection A critical review of amifostine as a cytoprotector in radiotherapy. Semin Radiat Oncol. 13:2003;62-72.
10. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 26:1999;3-21.
11. Ito H., Komaki R., Milas L. Protection by WR-2721 against radiation plus cisdiamminedichloroplatinum II caused injury to colonic epithelium mice. Int J Radiat Oncol Biol Phys. 28:1994;899-904.
12. American Joint Committee on Cancer. Manual for cancer staging. 5th ed:1998;JB Lippincott, Philadelphia.
13. Karnofsky D.A., Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. Macleod C.M. Evaluation of chemotherapeutic agents. 1949;191-205 Columbia University Press, New York.
14. Cox J.D., Azarnia N., Byhardt R.W., et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy Possible survival benefit with ≥69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 8:1990;1543-1555.
15. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;915-922.
16. StataCorp. Stata statistical software Release 7.0. 2001;Stata Corporation, College Station, TX.
17. Klein J.P., Moeschberger M.L. Survival analysis Techniques for censored and truncated data. 1997;Springer-Verlag, New York.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
19. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 4:1985;87-90.
20. Movsas B., Scott C., Langer C., et al. Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy and hyperfractionated radiation (chemo/HFxRT) Radiation Therapy Oncology Group (RTOG) 98-01. Grunberg S.M. Proceedings of the American Society of Clinical Oncology. 2003;636 American Society of Clinical Oncology, Chicago.
21. Komaki R., Travis E.L., Cox J.D. The lung and thymus. Cox J.D., Ang K.K. Radiation oncology: Rationale, technique, results. 8th ed:2003;399-426 Mosby, St. Louis.
22. Food and Drug Administration. Ethyol (amifostine) for injection. 1999
23. Senzer N. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification Preliminary findings. Semin Oncol. 29:2002;38-41.
24. Leong S.S., Tan E.H., Fong K.w, et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 21:2003;1767-1774.
25. Antonadou D., Throuvalas N., Petridis A., et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 57:2003;402-408.